Curevac Vaccine Status. Phase IIbIII CVnCoV is German clinical-stage biopharmaceutical company CureVacs mRNA-based vaccine candidate which started development in January 2020. The biotech company CureVac stops its first corona vaccine candidate.
CVnCoV is being developed in collaboration with British pharma giant GlaxoSmithKline GSK and Bayer. Starting in January 2021 CureVac forged a series of partnerships with pharmaceutical giants Bayer Celonic GSK and Novartis to support the production of their vaccine and develop new ones. CureVac now wants to develop a new vaccine.
Germanys CureVac is on track to file for European approval of its COVID-19 vaccine as early as this month because high infection rates among trial participants are bringing a read-out on efficacy within closer reach.
But with the final end for the primary Covid vaccine candidate Curevac is now falling back to the status of a biotech company in the early phase of product development. Ad FDA has authorized the Moderna COVID-19 Vaccine under an Emergency Use Authorization. The companys stock fell today on the news. Even at this low dose systemic AEs occurred more frequently in response to a prime dose compared to the modified mRNA vaccines.
